🔗 Share this article

While the US continues making unprecedented changes to its vaccination recommendations, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines in the global health crisis and has concentrated on alleged deaths following COVID-19 immunization in her brief position at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Schedule

Public health authorities were set to announce sweeping revisions to the childhood vaccine schedule recently, aligning the US with the Danish national calendar, it is understood – a significant shift that would put the US out of alignment with a large portion of the international standard with little proof for public health gain. This reveal has been postponed until the coming year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth person to lead the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific pediatric vaccine recommendations in the US in order to be more like Denmark's approach, a society with nationalized medicine and a citizenry about the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – traditionally the purview of Prasad, head of the FDA’s CBER – rather than medication approval.

Doubts Over Background

Dr. Høeg has no obvious track record in medication creation, approval processes or management, which has been standard for past directors of the biologics center. She has served at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in managing a sizeable institution. She is not an expert in drug approvals.”

Past commissioners of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she lacks the sort of resume that former directors who ran CBER have had.”

The drug center has an vast range of responsibilities at the FDA, the former commissioner stated.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous generic medications. There is also a biosimilars program, OTC medication office and so forth, and each of these need to be supervised,” she said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant administrative element to the job, which manages more than 5,000 personnel. “It’s a huge leadership role, if you do it right,” the former official concluded.

Agency Reaction and Disputed Policies

When asked about concerns about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among agency officials on immunizations, a press secretary stated that the “inquiries are based on incorrect premises”.

“Her experience matches the duties of her job,” the official said, noting the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's recently launched priority voucher program, a controversial one-day therapy clearance system that allegedly worried her predecessors. “By what process are these drugs being picked for this voucher program? Who makes the calls?” Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he said, “the agency looks to be trending towards laxer oversight of most medications, except for shots.”

Established Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if troubling, track record, some experts observe. She authored a analysis using unverified public submissions to determine the frequency of heart inflammation after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the incoming government encompassed altering regulations for recently developed shots and halting “unnecessary” vaccines, she said post-election on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She’s an complete dogmatist who commences with her preconceived notions and reverse-engineers to retrofit the science in a highly misleading, fraudulent fashion,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|